Cannabinoid Awareness, Reporting Use to Health Care Providers, and Perceptions Regarding Safety - Pennsylvania, March 2023-April 2023.

Q1 Medicine Medical Cannabis and Cannabinoids Pub Date : 2024-07-17 eCollection Date: 2024-01-01 DOI:10.1159/000539956
Paul T Kocis, Daniel J Mallinson, Timothy J Servinsky
{"title":"Cannabinoid Awareness, Reporting Use to Health Care Providers, and Perceptions Regarding Safety - Pennsylvania, March 2023-April 2023.","authors":"Paul T Kocis, Daniel J Mallinson, Timothy J Servinsky","doi":"10.1159/000539956","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>With the continued societal and policy interest in cannabinoids, the Penn State Harrisburg Center for Survey Research (CSR) conducted a web survey (Cannabinoid Lion Poll) for adult-aged Pennsylvanians between March 6 and April 2, 2023.</p><p><strong>Methods: </strong>The Lion Poll omnibus survey asked questions of adult-aged Pennsylvanians to assess awareness of cannabidiol (CBD) and products containing tetrahydrocannabinol (THC), including marijuana, the likelihood of reporting cannabinoid use to health care providers (HCPs), and perceptions regarding safety.</p><p><strong>Results: </strong>Of these 1,045 respondents, 51.2% were female; 83.0% were white, non-Hispanic; and 48.6% and 27.5% were within the 35-64-year and 18-34-year age ranges, respectively. Of the respondents, 52.1% and 53.9% told their HCPs they took CBD or products containing THC, respectively. Alcohol was perceived by the large proportion of respondents as unsafe (47.3%), followed by products containing THC (25.2%), anxiety/depression medications (21.7%), CBD (16.1%), and over-the-counter (OTC) pain medications (8.1%). Most combinations were perceived to be unsafe when asked to consider the safety of taking them with other prescription medications. Again, alcohol was perceived to be unsafe by the largest proportion (77.4%), followed by anxiety/depression medications (43.2%), products containing THC (42.6%), CBD (33.4%), and then OTC pain medications (24.8%).</p><p><strong>Conclusions: </strong>Adult-aged Pennsylvanians perceive CBD and THC containing products as safer than alcohol. There is considerable underreporting of cannabinoid use to HCPs, and therefore significant implications for patient safety. It remains vital that HCPs have open communications with their patients about cannabinoid use.</p>","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":"7 1","pages":"119-124"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324245/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000539956","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: With the continued societal and policy interest in cannabinoids, the Penn State Harrisburg Center for Survey Research (CSR) conducted a web survey (Cannabinoid Lion Poll) for adult-aged Pennsylvanians between March 6 and April 2, 2023.

Methods: The Lion Poll omnibus survey asked questions of adult-aged Pennsylvanians to assess awareness of cannabidiol (CBD) and products containing tetrahydrocannabinol (THC), including marijuana, the likelihood of reporting cannabinoid use to health care providers (HCPs), and perceptions regarding safety.

Results: Of these 1,045 respondents, 51.2% were female; 83.0% were white, non-Hispanic; and 48.6% and 27.5% were within the 35-64-year and 18-34-year age ranges, respectively. Of the respondents, 52.1% and 53.9% told their HCPs they took CBD or products containing THC, respectively. Alcohol was perceived by the large proportion of respondents as unsafe (47.3%), followed by products containing THC (25.2%), anxiety/depression medications (21.7%), CBD (16.1%), and over-the-counter (OTC) pain medications (8.1%). Most combinations were perceived to be unsafe when asked to consider the safety of taking them with other prescription medications. Again, alcohol was perceived to be unsafe by the largest proportion (77.4%), followed by anxiety/depression medications (43.2%), products containing THC (42.6%), CBD (33.4%), and then OTC pain medications (24.8%).

Conclusions: Adult-aged Pennsylvanians perceive CBD and THC containing products as safer than alcohol. There is considerable underreporting of cannabinoid use to HCPs, and therefore significant implications for patient safety. It remains vital that HCPs have open communications with their patients about cannabinoid use.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
大麻素认知、向医疗保健提供者报告使用情况以及对安全性的看法 - 宾夕法尼亚州,2023 年 3 月至 2023 年 4 月。
简介:随着社会和政策对大麻素的持续关注,宾夕法尼亚州立哈里斯堡调查研究中心(CSR)在 2023 年 3 月 6 日至 4 月 2 日期间对宾夕法尼亚州的成年居民进行了一项网络调查(大麻素狮子民意调查):Lion Poll 综合调查向宾夕法尼亚州的成年居民提出问题,以评估他们对大麻二酚 (CBD) 和含有四氢大麻酚 (THC) 的产品(包括大麻)的认识、向医疗保健提供者 (HCP) 报告大麻使用情况的可能性以及对安全性的看法:在 1,045 名受访者中,51.2% 为女性;83.0% 为非西班牙裔白人;年龄在 35-64 岁和 18-34 岁之间的受访者分别占 48.6% 和 27.5%。在受访者中,分别有 52.1% 和 53.9% 的人告诉他们的保健医生他们服用 CBD 或含有四氢大麻酚的产品。大部分受访者认为酒精不安全(47.3%),其次是含有 THC 的产品(25.2%)、焦虑/抑郁药物(21.7%)、CBD(16.1%)和非处方(OTC)止痛药(8.1%)。当被要求考虑与其他处方药一起服用的安全性时,大多数组合药物被认为是不安全的。同样,认为酒精不安全的比例最高(77.4%),其次是焦虑/抑郁药物(43.2%)、含有四氢大麻酚的产品(42.6%)、CBD(33.4%),然后是非处方药止痛药(24.8%):宾夕法尼亚州的成年人认为 CBD 和含 THC 的产品比酒精更安全。向保健医生报告大麻素使用情况的人数严重不足,因此对患者安全产生了重大影响。保健医生与患者就大麻素的使用进行坦诚交流仍然至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
期刊最新文献
Proceedings of the 2024 Cannabis Clinical Outcomes Research Conference. Development and in vitro Evaluation of Cannabidiol Mucoadhesive Buccal Film Formulations Using Hot-Melt Extrusion Technology. Cannabinoids for the Treatment of Glaucoma: A Review. Long-Term Treatment for Unspecified Anxiety Disorders with Cannabidiol: A Retrospective Case Series from Real-World Evidence in Colombia. Use of Cannabidiol-Dominant Extract as Co-Adjuvant Therapy for Type 2 Diabetes Mellitus Treatment in Feline: Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1